An Observational Study to Assess Optive MEGA-3 (OM3) on Dry Eye Symptoms and Quality of Life of Adult Participants With Mild to Moderate Dry Eye Disease (DED)
Completed · NCT06439394
Conditions: Dry Eye
At a glance
- Research payments reported, 2025
- $113,746
- U.S. investigators named
- 1
- Sites paid
- 1
- Planned or actual enrollment
- 52
About the trial
- Sponsor
- AbbVie
- Tested
- Optive MEGA-3 (OM3) (drug)
- Dates
- Started 2024-06-17; completion 2024-07-18
- Results posted
- Not yet
Dry Eye Disease (DED) is a condition where the tear film of the eye becomes unstable and along with ocular surface inflammation and damage leads to inadequate tear production and eye lubrication. This study will evaluate real-world experiences with Optive MEGA-3 (OM3) on relieving dry eye symptoms in adult participants with DED. OM3 is an over the counter (OTC) monograph drug indicated for the temporary relief of symptoms of eye dryness. Participants will administer 1 drop of OM3 on Day 1 for the acute phase of the study, then participants will administer 1-2 eye drops in each eye at least twice a day but as much as needed through Day 15. Around 50 adult participants will be enrolled at o…
From ClinicalTrials.gov, last updated 2025-08-19. Full record, eligibility and contacts (opens in a new tab)
Industry funding
AbbVie Inc. reported $113,746 in research payments for this study in 2025 (2 payments).
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- Southern College of Optom $113,746
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.